Is Opus Genetics, Inc. (IRD) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.0% / 30% | 9.0% / 30% | 1.7% / 30% | 213.41% / 5% | ✗ NOT HALAL |
| DJIM | 0.0% / 33% | 9.0% / 33% | 1.7% / 33% | 213.41% / 5% | ✗ NOT HALAL |
| MSCI | 0.0% / 33% | 82.3% / 33% | 15.7% / 33% | 213.41% / 5% | ✗ NOT HALAL |
| S&P | 0.0% / 33% | 9.0% / 33% | 1.7% / 33% | 213.41% / 5% | ✗ NOT HALAL |
| FTSE | 0.0% / 33% | 82.3% / 33% | 15.7% / 50% | 213.41% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | -117.0% | |
| Operating Margin | -296.3% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -242.4% | |
| Return on Assets (ROA) | -55.4% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$35M |
| Free Cash Flow | -$35M |
| Total Debt | $1M |
| Debt-to-Equity | 7.4 |
| Current Ratio | 6.4 |
| Total Assets | $50M |
Price & Trading
| Last Close | $4.52 |
| 50-Day MA | $3.67 |
| 200-Day MA | $2.12 |
| Avg Volume | 940K |
| Beta | 0.6 |
|
52-Week Range
$0.65
| |
About Opus Genetics, Inc. (IRD)
Opus Genetics, Inc., a clinical-stage biopharmaceutical company, develops gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. It develops OPGx-LCA5, an early-onset retinal degeneration that is in Phase 1/2 clinical trial for the treatment of LCA5-associated IRD; and OPGx-BEST1 to treat BEST1-associated retinal disease. The company also develops various pre-clinical IRD programs, including OPGx-RHO, a gene therapy that targets autosomal dominant retinitis pigmentosa caused by RHO mutations; OPGx-RDH12 that is designed to restore protein expression and halt functional deterioration in patients with retinal dystrophy caused by mutations in the retinal dehydrogenase gene; OPGx-MERTK, an AAV vector for the treatment of MERTK IRD; OPGx-NMNAT1, a gene augmentation therapy designed to halt functional deterioration in pediatric patients with retinal degenerative disease caused by mutations in the nicotinamide mononucleotide adenylyltransferase 1 gene; and OPGx-CNGB1, an AAV gene therapy for retinitis pigmentosa due to mutations in the CNGB1 gene. In addition, it develops Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as for the treatment of presbyopia and dim light or night vision disturbances and APX3330, a small-molecule inhibitor of Ref-1 for the treatment of diabetic retinopathy. Opus Genetics, Inc. was formerly known as Ocuphire Pharma, Inc. and changed its name to Opus Genetics, Inc. in November 2020. The company was founded in 2018 and is headquartered in Durham, North Carolina.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Opus Genetics, Inc. (IRD) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Opus Genetics, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Opus Genetics, Inc.'s debt ratio?
Opus Genetics, Inc.'s debt ratio is 0.0% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 0.0%.
What are Opus Genetics, Inc.'s key financial metrics?
Opus Genetics, Inc. has a market capitalization of $309M, and revenue of $14M. Return on equity stands at -242.4%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.